title: Immune response markers in sentinel nodes may predict melanoma progression.
abstract: We recently reported that variable expression of immune-response genes distinguishes tumor positive sentinel nodes in melanoma patients with malignant progression from those with non-progressing disease. Our results depict sentinel nodes as sites in which immune functions are associated with metastatic disease and identify CD30 as a host immune-related cancer prognostic marker and potential therapeutic target.
authors: Unit of Immunotherapy; Fondazione IRCCS Istituto Nazionale Tumori; Milan, Italy.
authors: Monica
authors: M
authors: Rodolfo
authors: Unit of Immunotherapy; Fondazione IRCCS Istituto Nazionale Tumori; Milan, Italy.
authors: Chiara
authors: C
authors: Castelli
authors: Unit of Immunotherapy; Fondazione IRCCS Istituto Nazionale Tumori; Milan, Italy.
authors: Licia
authors: L
authors: Rivoltini
keywords: CD30; expression profiles; lymph node; melanoma; sentinel node